市場調査レポート

商品コード

1454092

コロナウイルスワクチンの2030年までの市場予測：ワクチンタイプ別、年齢層別、投与経路別、流通チャネル別、技術別、地域別の世界分析

Coronavirus Vaccine Market Forecasts to 2030 - Global Analysis By Vaccine Type, Age Group, Route of Administration, Distribution Channel, Technology and By Geography

出版日: 2024年03月03日 | 発行: Stratistics Market Research Consulting

| ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,150 652,131円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 824,985円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 997,839円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,178,550円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、コロナウイルスワクチンの世界市場は2023年に439億米ドルを占め、2030年にはCAGR 9.4%で成長し823億米ドルに達すると予測されています。

コロナウイルスワクチンは、COVID-19の原因となる新型コロナウイルス、SARS-CoV-2に対する免疫を提供するために開発された医療用物質です。体内の免疫系を刺激してウイルスを認識・中和し、感染を予防したり、感染した場合の症状の重篤度を軽減したりします。ほとんどのワクチンは、ウイルスがヒトの細胞に侵入する際に使用するスパイク・タンパク質を標的としています。mRNAワクチン、ウイルスベクターワクチン、プロテインサブユニットワクチン、不活化ウイルスワクチンなど、さまざまな種類のワクチンが開発され、世界的に緊急時の使用が許可されています。

米国立衛生研究所（NIH）によると、ファイザー・バイオNTechのCOVID-19ワクチンは、2021年8月23日にFDAから商業化の承認を受けた。

世界の緊急ニーズ

COVID-19パンデミックは前例のない世界的影響を及ぼし、広範な疾病、死亡、経済的混乱、社会的大混乱を引き起こしました。ワクチンは、ウイルスの蔓延を抑え、ヘルスケアシステムの負担を軽減し、最終的には人命を救うための重要な手段であると認識されています。さらに、政府、ヘルスケア組織、一般市民は、大規模なワクチンの開発、製造、配布が急務であることを痛感しています。この緊急性は、ウイルスの新型の出現によってさらに高まっており、ワクチン開発における継続的な警戒と適応の必要性が強調され、市場の需要を加速させています。

製造上の制約

COVID-19ワクチンに対する世界の急速な需要は、製造能力を逼迫させ、供給不足、製造の遅延、流通の課題につながっています。ワクチン製造工程の複雑さ、ワクチン製造のための限られた製造施設、原材料や特殊機器の不足など、いくつかの要因がこうした制約の原因となっています。さらに、mRNAワクチンの製剤に使用される脂質ナノ粒子などの重要な成分の不足は、製造スケジュールを混乱させ、生産能力を制限する可能性があります。その結果、製造上の制約が市場の需要を妨げる大きな要因となっています。

政府の支援

COVID-19の大流行が公衆衛生に前例のない課題を突きつけていることから、世界各国の政府はワクチン開発、生産、流通の取り組みを加速させるため、多大な資源、資金、規制上の支援を動員しています。さらに、政府はワクチン開発のスケジュールを早め、製造能力を拡大するために、製薬会社や研究機関に対して財政的投資、研究助成金、インセンティブを提供してきました。したがって、政府の支援は市場の需要を促進する要因となっています。

ワクチンの有効性と安全性への懸念

ワクチンの有効性と安全性に関する懸念は、コロナウイルスワクチン市場の大きな抑制要因となっています。ワクチンの有効性に関する懸念は、ワクチンがどの程度感染を予防するか、または疾患の重症度を軽減するかに関連しています。また、ワクチンの安全性に関する懸念は、潜在的な副作用や健康への長期的影響を含んでいます。血液凝固障害や心筋炎など、ワクチン接種後に稀ではあるが重篤な有害事象が報告されたことで、懸念が高まり、ワクチンの安全性に対する社会的信頼が損なわれ、市場成長に影響を与えています。

COVID-19の影響

COVID-19がコロナウイルスワクチン市場に与えた影響は甚大かつ多面的でした。COVID-19は科学者、研究者、製薬会社、政府間の前例のない共同研究を促し、ワクチン開発のスケジュールを加速させました。さらに、パンデミックは、mRNAやウイルスベクター・プラットフォームなどの革新的なワクチン技術の迅速な展開を必要とし、記録的な速さで複数のCOVID-19ワクチンの開発と承認につながった。

予測期間中、RNAワクチン分野が最大となる見込み

RNAワクチン分野が最大のシェアを占めると推定されます。これらのワクチンは、メッセンジャーRNA（mRNA）に基づく新規技術を利用して、体内の細胞にウイルスタンパク質の産生を指示し、ウイルスに対する免疫反応を引き起こします。RNAワクチンの開発には、迅速な生産や拡張性など、いくつかの利点があります。さらに、RNAワクチンは、mRNAの塩基配列を新たなウイルス株に合わせて更新することで、新たな変異型ウイルスを標的とするように容易に改良することができ、パンデミックの進化に対抗するための汎用性と適応性を高めることができます。

予測期間中、組換えワクチン分野のCAGRが最も高くなると予想される

組み換えワクチン分野は、予測期間中に有利な成長を遂げると予測されます。これらのワクチンは組換えDNA技術を用いて開発され、スパイクタンパク質をコードする遺伝子などSARS-CoV-2ウイルスの特定の遺伝子を酵母や哺乳類細胞などの宿主細胞に挿入し、ウイルスタンパク質を産生します。組み換えワクチンは生きたウイルス粒子を含まないため、病気を引き起こすリスクがないです。このため、免疫系が低下している人やその他の健康状態にある人に適しています。さらに、組換えワクチンの生産は拡張性が高く、世界の需要に合わせて迅速に規模を拡大することができます。

最大のシェアを占める地域

推定期間中、北米が最大の市場シェアを占めました。北米はワクチン革新の最前線にあり、同地域に本社を置く複数の大手製薬会社がCOVID-19ワクチン開発の陣頭指揮を執っています。これらの企業は、mRNAや組換えDNAなどの最先端技術を活用し、高い有効性と安全性を備えたワクチンを迅速に開発してきました。さらに、北米の各国政府は、ワクチン開発を迅速化し、自国民が広くワクチンを利用できるようにするため、多額の財政投資、規制支援、調達イニシアチブを提供しています。

CAGRが最も高い地域：

アジア太平洋地域は、人口の多さ、ヘルスケアの多様性、新興経済圏の存在により、予測期間中に収益性の高い成長を遂げることが期待されています。特に中国とインドは、ワクチン製造の主要プレーヤーとして台頭し、国内使用と世界の流通のためにCOVID-19ワクチンを大量生産しています。これらの国々は、製造能力と広範なワクチン製造インフラを活用し、国内外市場にワクチンを供給しています。さらに、アジア太平洋地域のいくつかの国々は、ワクチンの研究開発に積極的に参加し、パンデミックと闘う世界の取り組みに貢献しています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第11章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第12章企業プロファイル

Moderna
AstraZeneca
Sinopharm
Pfizer-BioNTech
Sinovac
Johnson & Johnson
Serum Institute of India
Bharat Biotech
Gamaleya Research Institute
Novavax
CureVac
CanSino Biologics
Sanofi-GSK
GlaxoSmithKline
Entos Pharmaceuticals

図表

List of Tables

Table 1 Global Coronavirus Vaccine Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
Table 3 Global Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
Table 4 Global Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
Table 5 Global Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
Table 6 Global Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
Table 7 Global Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
Table 8 Global Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
Table 9 Global Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
Table 10 Global Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
Table 11 Global Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
Table 12 Global Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 13 Global Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
Table 14 Global Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
Table 15 Global Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
Table 16 Global Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 17 Global Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 18 Global Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
Table 19 Global Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
Table 20 Global Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
Table 21 Global Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 22 Global Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
Table 23 Global Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
Table 24 Global Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
Table 25 Global Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
Table 26 Global Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
Table 27 Global Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 28 North America Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
Table 29 North America Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
Table 30 North America Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
Table 31 North America Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
Table 32 North America Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
Table 33 North America Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
Table 34 North America Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
Table 35 North America Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
Table 36 North America Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
Table 37 North America Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
Table 38 North America Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
Table 39 North America Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 40 North America Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
Table 41 North America Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
Table 42 North America Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
Table 43 North America Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 44 North America Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 45 North America Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
Table 46 North America Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
Table 47 North America Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
Table 48 North America Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 49 North America Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
Table 50 North America Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
Table 51 North America Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
Table 52 North America Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
Table 53 North America Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
Table 54 North America Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 55 Europe Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
Table 56 Europe Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
Table 57 Europe Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
Table 58 Europe Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
Table 59 Europe Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
Table 60 Europe Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
Table 61 Europe Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
Table 62 Europe Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
Table 63 Europe Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
Table 64 Europe Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
Table 65 Europe Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
Table 66 Europe Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 67 Europe Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
Table 68 Europe Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
Table 69 Europe Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
Table 70 Europe Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 71 Europe Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 72 Europe Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
Table 73 Europe Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
Table 74 Europe Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
Table 75 Europe Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 76 Europe Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
Table 77 Europe Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
Table 78 Europe Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
Table 79 Europe Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
Table 80 Europe Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
Table 81 Europe Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 82 Asia Pacific Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
Table 83 Asia Pacific Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
Table 84 Asia Pacific Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
Table 85 Asia Pacific Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
Table 86 Asia Pacific Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
Table 87 Asia Pacific Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
Table 88 Asia Pacific Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
Table 89 Asia Pacific Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
Table 90 Asia Pacific Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
Table 91 Asia Pacific Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
Table 92 Asia Pacific Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
Table 93 Asia Pacific Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 94 Asia Pacific Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
Table 95 Asia Pacific Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
Table 96 Asia Pacific Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
Table 97 Asia Pacific Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 98 Asia Pacific Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 99 Asia Pacific Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
Table 100 Asia Pacific Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
Table 101 Asia Pacific Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
Table 102 Asia Pacific Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 103 Asia Pacific Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
Table 104 Asia Pacific Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
Table 105 Asia Pacific Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
Table 106 Asia Pacific Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
Table 107 Asia Pacific Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
Table 108 Asia Pacific Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 109 South America Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
Table 110 South America Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
Table 111 South America Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
Table 112 South America Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
Table 113 South America Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
Table 114 South America Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
Table 115 South America Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
Table 116 South America Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
Table 117 South America Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
Table 118 South America Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
Table 119 South America Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
Table 120 South America Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 121 South America Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
Table 122 South America Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
Table 123 South America Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
Table 124 South America Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 125 South America Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 126 South America Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
Table 127 South America Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
Table 128 South America Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
Table 129 South America Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 130 South America Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
Table 131 South America Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
Table 132 South America Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
Table 133 South America Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
Table 134 South America Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
Table 135 South America Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 136 Middle East & Africa Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
Table 137 Middle East & Africa Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
Table 138 Middle East & Africa Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
Table 139 Middle East & Africa Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
Table 140 Middle East & Africa Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
Table 141 Middle East & Africa Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
Table 142 Middle East & Africa Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
Table 143 Middle East & Africa Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
Table 144 Middle East & Africa Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
Table 145 Middle East & Africa Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
Table 146 Middle East & Africa Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
Table 147 Middle East & Africa Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 148 Middle East & Africa Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
Table 149 Middle East & Africa Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
Table 150 Middle East & Africa Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
Table 151 Middle East & Africa Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 152 Middle East & Africa Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 153 Middle East & Africa Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
Table 154 Middle East & Africa Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
Table 155 Middle East & Africa Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
Table 156 Middle East & Africa Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 157 Middle East & Africa Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
Table 158 Middle East & Africa Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
Table 159 Middle East & Africa Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
Table 160 Middle East & Africa Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
Table 161 Middle East & Africa Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
Table 162 Middle East & Africa Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)

Product Code: SMRC25644

According to Stratistics MRC, the Global Coronavirus Vaccine Market is accounted for $43.9 billion in 2023 and is expected to reach $82.3 billion by 2030 growing at a CAGR of 9.4% during the forecast period. A Coronavirus Vaccine is a medical substance developed to provide immunity against the novel coronavirus, SARS-CoV-2, which causes COVID-19. It stimulates the body's immune system to recognize and neutralize the virus, preventing infection or reducing the severity of symptoms if exposure occurs. Most vaccines target the virus's spike protein, which it uses to enter human cells. Different types of vaccines, including mRNA, viral vector, protein subunit, and inactivated virus vaccines, have been developed and authorized for emergency use globally.

According to the National Institutes of Health (NIH), the Pfizer-BioNTech COVID-19 vaccine received FDA approval for commercialization on 23 August 2021.

Market Dynamics:

Driver:

Urgent global need

The COVID-19 pandemic had unprecedented global impact, causing widespread illness, death, economic disruption, and social upheaval. Vaccines are recognized as a critical tool in controlling the spread of the virus, reducing the burden on healthcare systems, and ultimately saving lives. Moreover, governments, healthcare organizations, and the public are acutely aware of the urgency to develop, produce, and distribute vaccines on a massive scale. The urgency is further heightened by the emergence of new variants of the virus, emphasizing the need for continued vigilance and adaptation in vaccine development, which has accelerated market demand.

Restraint:

Manufacturing constraints

The rapid global demand for COVID-19 vaccines has strained manufacturing capacities, leading to supply shortages, delays in production, and distribution challenges. Several factors contribute to these constraints, including the complexity of vaccine production processes, limited manufacturing facilities equipped for vaccine production, and shortages of raw materials and specialized equipment. Additionally, shortages of critical components, such as lipid nanoparticles used in mRNA vaccine formulations, can disrupt manufacturing timelines and limit production capacity. As a result, manufacturing constraints are a significant factor hampering market demand.

Opportunity:

Government support

With the COVID-19 pandemic posing unprecedented public health challenges, governments worldwide have mobilized substantial resources, funding, and regulatory support to accelerate vaccine development, production, and distribution efforts. Additionally, governments have provided financial investments, research grants, and incentives to pharmaceutical companies and research institutions to expedite vaccine development timelines and scale up manufacturing capacity. Therefore, government support is a factor propelling market demand.

Threat:

Vaccine efficacy and safety concerns

Vaccine efficacy and safety concerns represent a significant restraint in the coronavirus vaccine market. Concerns regarding vaccine efficacy relate to how well a vaccine prevents infection or reduces the severity of the disease. Additionally, safety concerns regarding vaccines encompass potential adverse reactions, side effects, or long-term health implications. Reports of rare but serious adverse events following vaccination, such as blood clotting disorders or myocarditis, have raised concerns, eroded public confidence in vaccine safety, and impacted market growth.

Covid-19 Impact

The impact of COVID-19 on the coronavirus vaccine market has been profound and multifaceted. COVID-19 spurred unprecedented collaboration among scientists, researchers, pharmaceutical companies, and governments to accelerate vaccine development timelines. Moreover, the pandemic necessitated the rapid deployment of innovative vaccine technologies, such as mRNA and viral vector platforms, leading to the development and approval of multiple COVID-19 vaccines in record time.

The RNA vaccine segment is expected to be the largest during the forecast period

The RNA vaccine segment is estimated to hold the largest share. These vaccines utilize a novel technology based on messenger RNA (mRNA) to instruct cells in the body to produce a viral protein, triggering an immune response against the virus. The development of RNA vaccines offers several advantages, including rapid production and scalability. Additionally, RNA vaccines can be easily modified to target new variants of the virus by updating the mRNA sequence to match emerging strains, enhancing their versatility and adaptability in combating the evolving nature of the pandemic.

The recombinant vaccines segment is expected to have the highest CAGR during the forecast period

The recombinant vaccines segment is anticipated to have lucrative growth during the forecast period. These vaccines are developed using recombinant DNA technology, where specific genes from the SARS-CoV-2 virus, such as those encoding the spike protein, are inserted into host cells, such as yeast or mammalian cells, to produce viral proteins. Recombinant vaccines do not contain live virus particles, eliminating the risk of causing disease. This makes them suitable for individuals with compromised immune systems or other health conditions. Furthermore, recombinant vaccine production is highly scalable and can be rapidly scaled up to meet global demand.

Region with largest share:

North America commanded the largest market share during the extrapolated period. North America has been at the forefront of vaccine innovation, with several leading pharmaceutical companies headquartered in the region spearheading the development of COVID-19 vaccines. These companies have leveraged cutting-edge technologies, such as mRNA and recombinant DNA, to rapidly develop vaccines with high efficacy and safety profiles. Furthermore, governments in North America have provided substantial financial investments, regulatory support, and procurement initiatives to expedite vaccine development and ensure widespread access to vaccines for their populations.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, due to its large population, diverse healthcare landscape, and emerging economies. China and India, in particular, have emerged as key players in vaccine manufacturing, producing large quantities of COVID-19 vaccines for domestic use and global distribution. These countries have leveraged their manufacturing capabilities and extensive vaccine production infrastructure to supply vaccines to both domestic and international markets. Moreover, several countries in the Asia-Pacific region have actively participated in vaccine research and development, contributing to the global effort to combat the pandemic.

Key players in the market

Some of the key players in the Coronavirus Vaccine Market include Moderna, AstraZeneca, Sinopharm, Pfizer-BioNTech, Sinovac, Johnson & Johnson, Serum Institute of India, Bharat Biotech, Gamaleya Research Institute, Novavax, CureVac, CanSino Biologics, Sanofi-GSK, GlaxoSmithKline and Entos Pharmaceuticals.

Key Developments:

In November 2023, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.

In July 2023, AstraZeneca, a global biopharmaceutical company, announced collaboration with Absci Corporation. This collaboration combines Absci's Integrated Drug Creation(TM) platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate.

In January 2022, Pfizer Inc. and BioNTech SE announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.

In April 2020, Johnson & Johnson announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to support the manufacturing of its lead investigational COVID-19 vaccine candidate.

Vaccine Types Covered:

Repurposed Vaccines
Inactivated Virus
Non-replicating Viral Vector
Protein Subunit
DNA Vaccine
RNA Vaccine

Age Groups Covered:

12 to 18
Above 18

Route of Administrations Covered:

Intradermal
Intramuscular
Intranasal
Other Route of Administrations

Distribution Channels Covered:

Hospitals and Clinics
Government Entities
Vaccination Centers
Other Distribution Channels

Technologies Covered:

Synthetic Vaccines
Recombinant Vaccines
Live Attenuated Vaccines
Conventional Vaccines
Other Technologies

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Coronavirus Vaccine Market, By Vaccine Type

5.1 Introduction
5.2 Repurposed Vaccines
5.3 Inactivated Virus
5.4 Non-replicating Viral Vector
5.5 Protein Subunit
5.6 DNA Vaccine
5.7 RNA Vaccine

6 Global Coronavirus Vaccine Market, By Age Group

6.1 Introduction
6.2 12 to 18
6.3 Above 18

7 Global Coronavirus Vaccine Market, By Route of Administration

7.1 Introduction
7.2 Synthetic Vaccines
7.3 Intradermal
7.4 Intramuscular
7.5 Intranasal
7.6 Other Route of Administrations

8 Global Coronavirus Vaccine Market, By Distribution Channel

8.1 Introduction
8.2 Hospitals and Clinics
8.3 Government Entities
8.4 Vaccination Centers
8.5 Other Distribution Channels

9 Global Coronavirus Vaccine Market, By Technology

9.1 Introduction
9.2 Synthetic Vaccines
9.3 Recombinant Vaccines
9.4 Live Attenuated Vaccines
9.5 Conventional Vaccines
9.6 Other Technologies

10 Global Coronavirus Vaccine Market, By Geography

10.1 Introduction
10.2 North America
- 10.2.1 US
- 10.2.2 Canada
- 10.2.3 Mexico
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 Italy
- 10.3.4 France
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
10.5 South America
- 10.5.1 Argentina
- 10.5.2 Brazil
- 10.5.3 Chile
- 10.5.4 Rest of South America
10.6 Middle East & Africa
- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa

11 Key Developments

11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 Company Profiling

12.1 Moderna
12.2 AstraZeneca
12.3 Sinopharm
12.4 Pfizer-BioNTech
12.5 Sinovac
12.6 Johnson & Johnson
12.7 Serum Institute of India
12.8 Bharat Biotech
12.9 Gamaleya Research Institute
12.10 Novavax
12.11 CureVac
12.12 CanSino Biologics
12.13 Sanofi-GSK
12.14 GlaxoSmithKline
12.15 Entos Pharmaceuticals

コロナウイルスワクチンの2030年までの市場予測：ワクチンタイプ別、年齢層別、投与経路別、流通チャネル別、技術別、地域別の世界分析

Coronavirus Vaccine Market Forecasts to 2030 - Global Analysis By Vaccine Type, Age Group, Route of Administration, Distribution Channel, Technology and By Geography

最大のシェアを占める地域

CAGRが最も高い地域：

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界のコロナウイルスワクチン市場：ワクチンタイプ別

第6章 世界のコロナウイルスワクチン市場：年齢層別

第7章 世界のコロナウイルスワクチン市場：投与経路別

第8章 世界のコロナウイルスワクチン市場：流通チャネル別

第9章 世界のコロナウイルスワクチン市場：技術別

第10章 世界のコロナウイルスワクチン市場：地域別

第11章 主な発展

第12章 企業プロファイル